![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Abbott Laboratories, Abbott Park, Illinois (S.R.), Amgen Inc., Thousand Oaks, California (G.K., J.T.S.), AstraZeneca Pharmaceuticals LP, Wilmington, Delaware (S.G.), Aventis, Bridgewater, New Jersey (S.P.K.), Bayer Corporation, West Haven, Connecticut (A.S.), Boehringer Ingelheim Corporation, Ridgefield, Connecticut, (D.T.), Eli Lilly and Company, Indianapolis, Indiana (J.T.C., L. N., S.A.W.), GlaxoSmithKline, Research Triangle Park, North Carolina (J.W.), Merck Research Laboratories, West Point, Pennsylvania (J.M.V.), Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts (L.G., G.M.), Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (H.J.E., V.F., J.M.), Pfizer Inc., Groton, Connecticut (R.S.O.), Procter & Gamble, Cincinnati, Ohio (A.R.), Sanofi-Syntelabo Inc., Malvern, Pennsylvania (F.S.), Wyeth, Collegeville, Pennsylavnia (T.D.B., J.K.)
Abstract
Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies. There is a common desire by regulatory authorities and by industry sponsors to harmonize approaches, to allow for a better assessment of the significance of findings across different studies and drugs. There is also a growing consensus for the standardization of cytochrome P450 (P450) probe substrates, inhibitors and inducers and for the development of classification systems to improve the communication of risk to health care providers and to patients. While existing guidances cover mainly P450-mediated drug interactions, the importance of other mechanisms, such as transporters, has been recognized more recently, and should also be addressed. This article was prepared by the Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism and Clinical Pharmacology Technical Working Groups and represents the current industry position. The intent is to define a minimal best practice for in vitro and in vivo pharmacokinetic drug-drug interaction studies targeted to development (not discovery support) and to define a data package that can be expected by regulatory agencies in compound registration dossiers.
This article has been cited by other articles:
|
|
 |
|
  D. B. Richards, G. A. Walker, A. Mandagere, M. H. Magee, and L. S. Henderson Effect of Ketoconazole on the Pharmacokinetic Profile of Ambrisentan J. Clin. Pharmacol., June 1, 2009; 49(6): 719 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Zhang, V. T. Ly, M. Lago, Y. Tian, J. Gan, W. G. Humphreys, and S. N. Comezoglu CYP3A4-Mediated Ester Cleavage as the Major Metabolic Pathway of the Oral Taxane 3'-tert-Butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel (BMS-275183) Drug Metab. Dispos., April 1, 2009; 37(4): 710 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Stoch, E. Friedman, A. Maes, K. Yee, Y. Xu, P. Larson, M. Fitzgerald, J. Chodakewitz, and J. A. Wagner Effect of Different Durations of Ketoconazole Dosing on the Single-Dose Pharmacokinetics of Midazolam: Shortening the Paradigm J. Clin. Pharmacol., April 1, 2009; 49(4): 398 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Patroneva, S. M. Connolly, P. Fatato, R. Pedersen, Q. Jiang, J. Paul, C. Guico-Pabia, J. A. Isler, M. E. Burczynski, and A. I. Nichols An Assessment of Drug-Drug Interactions: The Effect of Desvenlafaxine and Duloxetine on the Pharmacokinetics of the CYP2D6 Probe Desipramine in Healthy Subjects Drug Metab. Dispos., December 1, 2008; 36(12): 2484 - 2491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gao, L. Yao, H. W. Mathieu, Y. Zhang, T. S. Maurer, M. D. Troutman, D. O. Scott, R. B. Ruggeri, and J. Lin In Silico Modeling of Nonspecific Binding to Human Liver Microsomes Drug Metab. Dispos., October 1, 2008; 36(10): 2130 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Murphy The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 3, 1984-2008 Drug Metab. Dispos., October 1, 2008; 36(10): 1977 - 1982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B Ibrahim, M. H Abidi, L. J Ayash, S. M Cronin, C. Cadotte, J. Mulawa, P. A Jacobson, D. W Smith, J. P Uberti, and D. J Edwards Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation Journal of Oncology Pharmacy Practice, September 1, 2008; 14(3): 113 - 121. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Bell, S. Bickford, P. H. Nguyen, J. Wang, T. He, B. Zhang, Y. Friche, A. Zimmerlin, L. Urban, and D. Bojanic Evaluation of Fluorescence- and Mass Spectrometry--Based CYP Inhibition Assays for Use in Drug Discovery J Biomol Screen, June 1, 2008; 13(5): 343 - 353. [Abstract] [PDF]
|
|
|
|
|
|
K. Minato, R. Suzuki, A. Asagarasu, T. Matsui, and M. Sato Biotransformation of 3-Amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878), a Novel 5-Hydroxytryptamine (5-HT)1A Agonist/5-HT3 Antagonist, in Human Hepatic Cytochrome P450 Enzymes Drug Metab. Dispos., May 1, 2008; 36(5): 831 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Klieber, S. Hugla, R. Ngo, C. Arabeyre-Fabre, V. Meunier, F. Sadoun, O. Fedeli, M. Rival, M. Bourrie, F. Guillou, et al. Contribution of the N-Glucuronidation Pathway to the Overall in Vitro Metabolic Clearance of Midazolam in Humans Drug Metab. Dispos., May 1, 2008; 36(5): 851 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G. van de Kerkhof, I. A. M. de Graaf, A.-L. B. Ungell, and G. M. M. Groothuis Induction of Metabolism and Transport in Human Intestine: Validation of Precision-Cut Slices as a Tool to Study Induction of Drug Metabolism in Human Intestine in Vitro Drug Metab. Dispos., March 1, 2008; 36(3): 604 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gertz, P. J. Kilford, J. B. Houston, and A. Galetin Drug Lipophilicity and Microsomal Protein Concentration as Determinants in the Prediction of the Fraction Unbound in Microsomal Incubations Drug Metab. Dispos., March 1, 2008; 36(3): 535 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ohno, K. Nakayama, S. Nakade, J. Kitagawa, S. Ueda, H. Miyabe, Y. Miyata, and A. Ohnishi Effect of Itraconazole on the Pharmacokinetics of Imidafenacin in Healthy Subjects J. Clin. Pharmacol., March 1, 2008; 48(3): 330 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Kanebratt and T. B. Andersson HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans Drug Metab. Dispos., January 1, 2008; 36(1): 137 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Farid, C. D. Payne, C. S. Ernest II, Y. G. Li, K. J. Winters, D. E. Salazar, and D. S. Small Prasugrel, a New Thienopyridine Antiplatelet Drug, Weakly Inhibits Cytochrome P450 2B6 in Humans J. Clin. Pharmacol., January 1, 2008; 48(1): 53 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zhang, D. Zhang, D. Cui, J. Gambardella, L. Ma, A. Barros, L. Wang, Y. Fu, S. Rahematpura, J. Nielsen, et al. Characterization of the UDP Glucuronosyltransferase Activity of Human Liver Microsomes Genotyped for the UGT1A1*28 Polymorphism Drug Metab. Dispos., December 1, 2007; 35(12): 2270 - 2280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Walsky and R. S. Obach A Comparison of 2-Phenyl-2-(1-piperidinyl)propane (PPP), 1,1',1''-Phosphinothioylidynetrisaziridine (ThioTEPA), Clopidogrel, and Ticlopidine as Selective Inactivators of Human Cytochrome P450 2B6 Drug Metab. Dispos., November 1, 2007; 35(11): 2053 - 2059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Cameron, J. Wright, C. B. Black, and N. Ye In Vitro Prediction and in Vivo Verification of Enantioselective Human Tofisopam Metabolite Profiles Drug Metab. Dispos., October 1, 2007; 35(10): 1894 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Seitz and H. Zhou Pharmacokinetic Drug-Drug Interaction Potentials for Therapeutic Monoclonal Antibodies: Reality Check J. Clin. Pharmacol., September 1, 2007; 47(9): 1104 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nagata, M. Hidaka, H. Sekiya, Y. Kawano, K. Yamasaki, M. Okumura, and K. Arimori Effects of Pomegranate Juice on Human Cytochrome P450 2C9 and Tolbutamide Pharmacokinetics in Rats Drug Metab. Dispos., February 1, 2007; 35(2): 302 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zhang, L. Wang, G. Chandrasena, L. Ma, M. Zhu, H. Zhang, C. D. Davis, and W. G. Humphreys Involvement of Multiple Cytochrome P450 and UDP-Glucuronosyltransferase Enzymes in the in Vitro Metabolism of Muraglitazar Drug Metab. Dispos., January 1, 2007; 35(1): 139 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H-H. S. Chow, I. A. Hakim, D. R. Vining, J. A. Crowell, C. A. Cordova, W. M. Chew, M.-J. Xu, C.-H. Hsu, J. Ranger-Moore, and D. S. Alberts Effects of Repeated Green Tea Catechin Administration on Human Cytochrome P450 Activity Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2473 - 2476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Z. Wang, J. Y. Saulter, E. Usuki, Y.-L. Cheung, M. Hall, A. S. Bridges, G. Loewen, O. T. Parkinson, C. E. Stephens, J. L. Allen, et al. CYP4F Enzymes Are the Major Enzymes in Human Liver Microsomes That Catalyze the O-Demethylation of the Antiparasitic Prodrug DB289 [2,5-Bis(4-amidinophenyl)furan-bis-O-methylamidoxime] Drug Metab. Dispos., December 1, 2006; 34(12): 1985 - 1994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chen, A. N. Nafziger, and J. S. Bertino Jr. Drug-Metabolizing Enzyme Inhibition by Ketoconazole Does Not Reduce Interindividual Variability of CYP3A Activity as Measured by Oral Midazolam Drug Metab. Dispos., December 1, 2006; 34(12): 2079 - 2082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G. van de Kerkhof, A.-L. B. Ungell, A. K. Sjoberg, M. H. de Jager, C. Hilgendorf, I. A. M. de Graaf, and G. M. M. Groothuis Innovative Methods to Study Human Intestinal Drug Metabolism in Vitro: Precision-Cut Slices Compared with Ussing Chamber Preparations Drug Metab. Dispos., November 1, 2006; 34(11): 1893 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhu, L. Ma, D. Zhang, K. Ray, W. Zhao, W. G. Humphreys, G. Skiles, M. Sanders, and H. Zhang Detection and Characterization of Metabolites in Biological Matrices Using Mass Defect Filtering of Liquid Chromatography/High Resolution Mass Spectrometry Data Drug Metab. Dispos., October 1, 2006; 34(10): 1722 - 1733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Ripp, J. B. Mills, O. A. Fahmi, K. A. Trevena, J. L. Liras, T. S. Maurer, and S. M. de Morais Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction Drug Metab. Dispos., October 1, 2006; 34(10): 1742 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-c. Lin, C. Fang, S. Benetton, G.-f. Xu, and L.-T. Yeh Metabolic Activation of Pradefovir by CYP3A4 and Its Potential as an Inhibitor or Inducer. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 2926 - 2931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Gibbs, R. Hyland, and K. Youdim Minimizing Polymorphic Metabolism in Drug Discovery: Evaluation of the Utility of in Vitro Methods for Predicting Pharmacokinetic Consequences Associated with CYP2D6 Metabolism Drug Metab. Dispos., September 1, 2006; 34(9): 1516 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Chien, A. Lucksiri, C. S. Ernest II, J. C. Gorski, S. A. Wrighton, and S. D. Hall STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE Drug Metab. Dispos., July 1, 2006; 34(7): 1208 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liu, J.-W. Zhang, W. Li, H. Ma, J. Sun, M.-C. Deng, and L. Yang Ginsenoside Metabolites, Rather Than Naturally Occurring Ginsenosides, Lead to Inhibition of Human Cytochrome P450 Enzymes Toxicol. Sci., June 1, 2006; 91(2): 356 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Zhang, S. S. Dehal, T. Ho, J. Johnson, C. Chandler, A. P. Blanchard, R. J. Clark Jr., C. L. Crespi, D. M. Stresser, and J. Wong HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81 Drug Metab. Dispos., May 1, 2006; 34(5): 734 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Hesse, D. J. Greenblatt, L. L. von Moltke, and M. H. Court Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J. Clin. Pharmacol., May 1, 2006; 46(5): 567 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Johnson, I. H. Song, K. K. Adkison, J. Borland, L. Fang, Y. Lou, M. M. Berrey, A. N. Nafziger, S. C. Piscitelli, and J. S. Bertino Jr Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail. J. Clin. Pharmacol., May 1, 2006; 46(5): 577 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hallifax and J. B. Houston BINDING OF DRUGS TO HEPATIC MICROSOMES: COMMENT AND ASSESSMENT OF CURRENT PREDICTION METHODOLOGY WITH RECOMMENDATION FOR IMPROVEMENT Drug Metab. Dispos., April 1, 2006; 34(4): 724 - 726. [Full Text] [PDF]
|
|
|
|
|
|
A. Ghosal, S. K. Chowdhury, W. Tong, N. Hapangama, Y. Yuan, A.-D. Su, and S. Zbaida IDENTIFICATION OF HUMAN LIVER CYTOCHROME P450 ENZYMES RESPONSIBLE FOR THE METABOLISM OF LONAFARNIB (SARASAR) Drug Metab. Dispos., April 1, 2006; 34(4): 628 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Chang, D. E. Moody, and E. F. McCance-Katz NOVEL METABOLITES OF BUPRENORPHINE DETECTED IN HUMAN LIVER MICROSOMES AND HUMAN URINE Drug Metab. Dispos., March 1, 2006; 34(3): 440 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Williams, K. Johnson, J. Paulauskis, and J. Cook So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J. Clin. Pharmacol., March 1, 2006; 46(3): 258 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Galetin, H. Burt, L. Gibbons, and J. B. Houston PREDICTION OF TIME-DEPENDENT CYP3A4 DRUG-DRUG INTERACTIONS: IMPACT OF ENZYME DEGRADATION, PARALLEL ELIMINATION PATHWAYS, AND INTESTINAL INHIBITION Drug Metab. Dispos., January 1, 2006; 34(1): 166 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W. Ogilvie, D. Zhang, W. Li, A. D. Rodrigues, A. E. Gipson, J. Holsapple, P. Toren, and A. Parkinson GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS Drug Metab. Dispos., January 1, 2006; 34(1): 191 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Obach, R. L. Walsky, K. Venkatakrishnan, E. A. Gaman, J. B. Houston, and L. M. Tremaine The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 336 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Atkinson, J. R. Kenny, and K. Grime AUTOMATED ASSESSMENT OF TIME-DEPENDENT INHIBITION OF HUMAN CYTOCHROME P450 ENZYMES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ANALYSIS Drug Metab. Dispos., November 1, 2005; 33(11): 1637 - 1647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Kharasch, A. Walker, C. Hoffer, and P. Sheffels Sensitivity of Intravenous and Oral Alfentanil and Pupillary Miosis as Minimally Invasive and Noninvasive Probes for Hepatic and First-Pass CYP3A Activity J. Clin. Pharmacol., October 1, 2005; 45(10): 1187 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Katoh, T. Matsui, H. Okumura, M. Nakajima, M. Nishimura, S. Naito, C. Tateno, K. Yoshizato, and T. Yokoi EXPRESSION OF HUMAN PHASE II ENZYMES IN CHIMERIC MICE WITH HUMANIZED LIVER Drug Metab. Dispos., September 1, 2005; 33(9): 1333 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Bauman, T. C. Goosen, M. Tugnait, V. Peterkin, S. I. Hurst, L. C. Menning, M. Milad, M. H. Court, and J. A. Williams UDP-GLUCURONOSYLTRANSFERASE 2B7 IS THE MAJOR ENZYME RESPONSIBLE FOR GEMCABENE GLUCURONIDATION IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., September 1, 2005; 33(9): 1349 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-K. Lim, N. Duczak Jr., L. Brougham, M. Elliot, K. Patel, and K. Chan AUTOMATED SCREENING WITH CONFIRMATION OF MECHANISM-BASED INACTIVATION OF CYP3A4, CYP2C9, CYP2C19, CYP2D6, AND CYP1A2 IN POOLED HUMAN LIVER MICROSOMES Drug Metab. Dispos., August 1, 2005; 33(8): 1211 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Mohutsky, D. M. Petullo, and S. A. Wrighton THE USE OF A SUBSTRATE CASSETTE STRATEGY TO IMPROVE THE CAPACITY AND THROUGHPUT OF CYTOCHROME P450 INDUCTION STUDIES IN HUMAN HEPATOCYTES Drug Metab. Dispos., July 1, 2005; 33(7): 920 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Roymans, P. Annaert, J. Van Houdt, A. Weygers, J. Noukens, C. Sensenhauser, J. Silva, C. Van Looveren, J. Hendrickx, G. Mannens, et al. EXPRESSION AND INDUCTION POTENTIAL OF CYTOCHROMES P450 IN HUMAN CRYOPRESERVED HEPATOCYTES Drug Metab. Dispos., July 1, 2005; 33(7): 1004 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Galetin, K. Ito, D. Hallifax, and J. B. Houston CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 180 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Kharasch, K. E. Thummel, and P. B. Watkins CYP3A Probes Can Quantitatively Predict the In Vivo Kinetics of Other CYP3A Substrates and Can Accurately Assess CYP3A Induction and Inhibition Mol. Interv., June 1, 2005; 5(3): 151 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Venkatakrishnan and R. S. Obach IN VITRO-IN VIVO EXTRAPOLATION OF CYP2D6 INACTIVATION BY PAROXETINE: PREDICTION OF NONSTATIONARY PHARMACOKINETICS AND DRUG INTERACTION MAGNITUDE Drug Metab. Dispos., June 1, 2005; 33(6): 845 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A Bachmann and J. D Lewis Predicting Inhibitory Drug-Drug Interactions and Evaluating Drug Interaction Reports Using Inhibition Constants Ann. Pharmacother., June 1, 2005; 39(6): 1064 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhu, W. Zhao, H. Jimenez, D. Zhang, S. Yeola, R. Dai, N. Vachharajani, and J. Mitroka CYTOCHROME P450 3A-MEDIATED METABOLISM OF BUSPIRONE IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., April 1, 2005; 33(4): 500 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Kharasch, A. Walker, C. Hoffer, and P. Sheffels Evaluation of First-Pass Cytochrome P4503A (CYP3A) and P-Glycoprotein Activities Using Alfentanil and Fexofenadine in Combination J. Clin. Pharmacol., January 1, 2005; 45(1): 79 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Williams, R. Hyland, B. C. Jones, D. A. Smith, S. Hurst, T. C. Goosen, V. Peterkin, J. R. Koup, and S. E. Ball DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS Drug Metab. Dispos., November 1, 2004; 32(11): 1201 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. B. Agrawal, C. Z. Matthews, R. S. Mazenko, E. J. Woolf, A. G. Porras, X. Chen, J. L. Miller, N. Michiels, M. Wehling, A. Schultz, et al. The Effects of Modifying In Vivo Cytochrome P450 3A (CYP3A) Activity on Etoricoxib Pharmacokinetics and of Etoricoxib Administration on CYP3A Activity J. Clin. Pharmacol., October 1, 2004; 44(10): 1125 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Andersson, E. Bredberg, H. Ericsson, and H. Sjoberg AN EVALUATION OF THE IN VITRO METABOLISM DATA FOR PREDICTING THE CLEARANCE AND DRUG-DRUG INTERACTION POTENTIAL OF CYP2C9 SUBSTRATES Drug Metab. Dispos., July 1, 2004; 32(7): 715 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Cai, R. W. Wang, R. W. Edom, D. C. Evans, M. Shou, A. D. Rodrigues, W. Liu, D. C. Dean, and T. A. Baillie VALIDATION OF (-)-N-3-BENZYL-PHENOBARBITAL AS A SELECTIVE INHIBITOR OF CYP2C19 IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., June 1, 2004; 32(6): 584 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Sridar, T. C. Goosen, U. M. Kent, J. A. Williams, and P. F. Hollenberg SILYBIN INACTIVATES CYTOCHROMES P450 3A4 AND 2C9 AND INHIBITS MAJOR HEPATIC GLUCURONOSYLTRANSFERASES Drug Metab. Dispos., June 1, 2004; 32(6): 587 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Walsky and R. S. Obach VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES Drug Metab. Dispos., June 1, 2004; 32(6): 647 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Frye Probing the World of Cytochrome P450 Enzymes Mol. Interv., June 1, 2004; 4(3): 157 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-M. Huang and L. J. Lesko Drug-Drug, Drug-Dietary Supplement, and Drug-Citrus Fruit and Other Food Interactions: What Have We Learned? J. Clin. Pharmacol., June 1, 2004; 44(6): 559 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Stresser, M. I. Broudy, T. Ho, C. E. Cargill, A. P. Blanchard, R. Sharma, A. A. Dandeneau, J. J. Goodwin, S. D. Turner, J. C. L. Erve, et al. HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE Drug Metab. Dispos., January 1, 2004; 32(1): 105 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Geng A METHOD FOR IDENTIFICATION OF INHIBITION MECHANISM AND ESTIMATION OF KI IN IN VITRO ENZYME INHIBITION STUDY Drug Metab. Dispos., November 1, 2003; 31(11): 1456 - 1457. [Full Text] [PDF]
|
|
|
|
|
|
K. Ito, D. Hallifax, R. S. Obach, and J. B. Houston IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM Drug Metab. Dispos., June 1, 2005; 33(6): 837 - 844. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
